![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Pott, Christiane; Sehn, Laurie H.; Belada, David; Gribben, John; Hoster, Eva; Kahl, Brad; Kehden, Britta; Nicolas-Virelizier, Emmanuelle; Spielewoy, Nathalie; Fingerle-Rowson, Guenter; Harbron, Chris; Mundt, Kirsten; Wassner-Fritsch, Elisabeth und Cheson, Bruce D.
(Februar 2020):
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
In: Leukemia, Bd. 34, Nr. 2: S. 522-32
Morschhauser, Franck; Flinn, Ian W.; Advani, Ranjana; Sehn, Laurie H.; Diefenbach, Catherine; Kolibaba, Kathryn; Press, Oliver W.; Salles, Gilles; Tilly, Herve; Chen, Andy I.; Assouline, Sarit; Cheson, Bruce D.; Dreyling, Martin; Hagenbeek, Anton; Zinzani, Pier Luigi; Jones, Surai; Cheng, Ji; Lu, Dan; Penuel, Elicia; Hirata, Jamie; Wenger, Michael; Chu, Yu-Waye und Sharman, Jeff
(2019):
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
In: Lancet Haematology, Bd. 6, Nr. 5, E254-E265
Cheson, Bruce D.; O'Brien, Susan; Ewer, Michael S.; Goncalves, Marcus D.; Farooki, Azeez; Lenz, Georg; Yu, Anthony; Fisher, Richard I.; Zinzani, Pierre L. und Dreyling, Martin
(2019):
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
In: Clinical Lymphoma Myeloma & Leukemia, Bd. 19, Nr. 3: S. 135-141
Cheson, Bruce D.; Brugger, Wolfram; Damaj, Gandhi; Dreyling, Martin; Kahl, Brad; Kimby, Eva; Ogura, Michinori; Weidmann, Eckhart; Wendtner, Clemens-Martin und Zinzani, Pier Luigi
(2016):
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
In: Leukemia & Lymphoma, Bd. 57, Nr. 4: S. 766-782